Christoph Nowak
Direttore Tecnico/Scientifico/R&S presso DIAMYD MEDICAL AB
Patrimonio netto: 837 $ in data 30/06/2024
Profilo
Christoph Nowak is currently an Independent Director at OncoZenge AB, a Chief Medical & Business Officer at Diamyd Medical AB, and a Chief Medical Officer at Melius Pharma AB.
Previously, he worked as an Assistant Professor at Karolinska Institutet.
He holds a doctorate degree from the University of Oxford, the University of Uppsala, and Technische Universität Braunschweig.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
31/08/2023 | 597 ( 0.00% ) | 837 $ | 30/06/2024 |
Posizioni attive di Christoph Nowak
Società | Posizione | Inizio |
---|---|---|
DIAMYD MEDICAL AB | Direttore Tecnico/Scientifico/R&S | - |
ONCOZENGE AB | Direttore/Membro del Consiglio | 09/09/2023 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Christoph Nowak
Società | Posizione | Fine |
---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - |
Formazione di Christoph Nowak
University of Uppsala | Doctorate Degree |
University of Oxford | Doctorate Degree |
Technische Universität Braunschweig | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
DIAMYD MEDICAL AB | Health Technology |
ONCOZENGE AB | Health Technology |
Aziende private | 1 |
---|---|
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Health Technology |
- Borsa valori
- Insiders
- Christoph Nowak